The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study

NCT06329037 | Recruiting

• 1 other identifier: BAM_lab_eye-tracking_01
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Conditions

Healthy

Keywords

Eye-tracking; vasopressin

Outcome Measures

Primary Outcomes (2)

• Saccade/antisaccade latency difference between social and non-social stimuli after oral vasopressin administration

  Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions.

  45 minutes - 75 minutes after treatment

• Error rate of saccade/antisaccade for social versus non-social stimuli after oral vasopressin administration

  Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions.

  45 minutes - 75 minutes after treatment

Secondary Outcomes (2)

• Saccade/antisaccade latency for different facial emotions after oral vasopressin administration

  45 minutes - 75 minutes after treatment

• Error rate of saccade/antisaccade for different facial emotions after oral vasopressin administration

  45 minutes - 75 minutes after treatment

Study Arms (2)

Vasopressin group

EXPERIMENTAL

Vasopressin (20IU)

Drug: Vasopressin

Placebo group

PLACEBO COMPARATOR

Placebo

Drug: Placebo

Interventions

Vasopressin DRUG

Administration of Vasopressin (20 IU) (oral spray)

Also known as: Antidiuretic Hormone

Vasopressin group

Placebo DRUG

Administration of Placebo (oral spray)

Also known as: Placebo treatment

Placebo group

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
• Normal or corrected-normal version

You may not qualify if:

• History of neuropsychiatric diseases.
• History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
• History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
• History of renal diseases, including renal stones or renal failure.
• History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
• Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
• Infections such as COVID-19 or influenza, or unexplained fever.
• Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
• History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
• Blood donation (≤ 1 month prior to administration).
• Take oral contraceptives or receive hormonal medications in the three months prior to the experiment.
• Pregnant or breastfeeding.

Sponsors & Collaborators

• University of Electronic Science and Technology of China: lead

Study Sites (1)

University of Electronic Science and Technology of China

Chengdu, Sichuan, 611731, China

RECRUITING

MeSH Terms

Conditions

Diabetes Insipidus

Interventions

Vasopressins

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pituitary Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins

Study Officials

• Benjamin Becker, Dr

  University of Electronic Science and Technology of China

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Weihua Zhao, Dr

CONTACT

86-28-61830811; zarazhao.uestc@outlook.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Randomized placebo-controlled double-blind between-subject design

Study Record Dates

• First Submitted: March 15, 2024
• First Posted: March 25, 2024
• Study Start: March 5, 2024
• Primary Completion: June 1, 2025
• Study Completion: July 30, 2025
• Last Updated: April 11, 2024

Record last verified: 2024-04

Locations

CN (1)